arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Connect Biopharma Holdings Ltd

CNTB

$2.21 ▲ +0.03 (+1.38%) at close

5 Visible periods

25 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Connect Biopharma Holdings Ltd faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $123.0M

Dividend Yield —

Revenue Growth -99.8%

Op. Margin None

ROIC -138.8% ↘

FCF / Share $-0.93 ↘

Trailing P/E —

Price / Book 3.0x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

5-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$64.00K

↓ -99.8% —

Net Income Profit after all expenses

$-55.48M

↓ -255.0% —

FCF / Share Free cash flow per share

$-0.93

↓ -110.3% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗
Revenue Growth YoY (%)	-99.8% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1347%)	—	—	—	—
EPS Growth YoY (%)	-257.1% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	75.2% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—
Net Income Growth YoY (%)	-255.0% Weak ↓ Weak Declining Year-over-year change in net income	74.8% Excellent ↑ Excellent Improving Year-over-year change in net income	47.4% Excellent Excellent Year-over-year change in net income	41.6% Excellent Excellent Year-over-year change in net income	—
FCF Growth YoY (%)	-110.3% Weak Weak Year-over-year change in free cash flow	49.2% Excellent Excellent Year-over-year change in free cash flow	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗
Operating Margin (%) (%)	—	-86.2% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-675%)	—	—	—
Effective Tax Rate (%) (%)	-0.4% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-1.4% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.2% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—
Profit Margin (%) (%)	—	-60.0% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-600%)	—	—	—
FCF Margin (%) (%)	—	-93.6% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—
FCF / Net Income (x)	0.93x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.56x Excellent Excellent Free cash flow relative to reported net income Optimal: > 1x	0.77x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗
Return on Invested Capital (%)	-138.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-24.7% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-68.2% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—
Return on Capital (%) (%)	-103.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-22.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	-54.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-132.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-981%)	-17.0% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-213%)	-61.2% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-508%)	—	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗
Net Debt (USD)	$-38.34M	$-78.23M	$-105.66M	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗
Revenue per Share (USD)	$0.00	$0.47	$0.00	—	—
Basic EPS, GAAP (USD)	$-1.00	$-0.28	$-1.13	—	—
Free Cash Flow per Share (USD)	$-0.93	$-0.44	$-0.87	—	—
Book Value per Share (USD)	$0.74	$1.67	$1.84	—	—
Tangible Book Value per Share (USD)	$0.74	$1.67	$1.84	—	—
Basic Weighted Avg Shares (shares)	55.66M	55.21M	55.07M	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗
Working Capital (USD)	$37.32M	$88.50M	$97.26M	—	—
Total Equity (USD)	$41.98M	$92.17M	$101.50M	—	—

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗
Sales/Revenue/Turnover (USD)	$64.00K	$26.03M	$0.00	—	—
Depreciation Expense (USD)	$704.00K	$660.00K	$720.00K	—	—
Net Income, GAAP (USD)	$-55.48M	$-15.63M	$-62.11M	$-118.09M	$-202.27M
Operating Cash Flow (USD)	$-51.21M	$-23.61M	$-47.74M	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 5 years · 12 quarters

Connect Biopharma Holdings Ltd

Analytical Summary

5-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare CNTB with peers